AT549337T
Purine derivatives for use as adenosin a2a receptor agonists
Abstract
A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, and their preparation and use as pharmaceuticalswherein R1, R 2 and R 3 are as defined herein. The compounds are useful for the treatment of a condition mediated by activation of the adenosine A2A receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions comprising a purine derivative as active ingredient and a process for the preparation of these compounds.
Term
0.6 yearsleft in the term
Expires 19 April 2027.
- Priority
- Filed
- Granted
- Today
- Expires
47 members in 30 offices
Priority claims3
| Document | Office | Kind | Date |
|---|---|---|---|
| 0607947 | United Kingdom | A | |
| 07101483 | European Patent Office (EPO) | A | |
| 2007003435 | European Patent Office (EPO) | W |
Members47
| Document | Office | Kind | |
|---|---|---|---|
| AU2007241343A1 | Australia | A1 | |
| CA2649215A1 | Canada | A1 | |
| WO2007121920A2 | World Intellectual Property Organization (WIPO) | A2 | |
| WO2007121920A3 | World Intellectual Property Organization (WIPO) | A3 | |
| TW200808797A | Taiwan Province of China | A | |
| AR060607A1 | Argentina | A1 | |
| MX2008013431A | Mexico | A | |
| NO20084803L | Norway | L | |
| KR20080110925A | Republic of Korea | A | |
| EP2013211A2 | European Patent Office (EPO) | A2 | |
| CR10335A | Costa Rica | A | |
| MA30469B1 | Morocco | B1 | |
| CN101472925A | China | A | |
| ZA200808055B | South Africa | B | |
| IL194396A0 | Israel | A0 | |
| HK1125642A | Hong Kong, China | A | |
| HK1125642A1 | Hong Kong, China | A1 | |
| JP2009534338A | Japan | A | |
| TNSN08407A1 | Tunisia | A1 | |
| RU2008145716A | Russian Federation | A | |
| US2010286126A1 | United States of America | A1 | |
| EP2322525A1 | European Patent Office (EPO) | A1 | |
| UA94735C2 | Ukraine | C2 | |
| AU2007241343B2 | Australia | B2 | |
| NZ571429A | New Zealand | A | |
| US2012004212A1 | United States of America | A1 | |
| US2012004247A1 | United States of America | A1 | |
| BRPI0710573A2 | Brazil | A2 | |
| EP2013211B1 | European Patent Office (EPO) | B1 | |
| AT549337TThis record | Austria | T | |
| ATE549337T1 | Austria | T1 | |
| CN101472925B | China | B | |
| PT2013211E | Portugal | E | |
| DK2013211T3 | Denmark | T3 | |
| ES2384337T3 | Spain | T3 | |
| RU2457209C2 | Russian Federation | C2 | |
| SI2013211T1 | Slovenia | T1 | |
| HRP20120494T1 | Croatia | T1 | |
| PL2013211T3 | Poland | T3 | |
| US8258141B2 | United States of America | B2 | |
| MY146645A | Malaysia | A | |
| US8318750B2 | United States of America | B2 | |
| EP2322525B1 | European Patent Office (EPO) | B1 | |
| JP5373599B2 | Japan | B2 | |
| PT2322525E | Portugal | E | |
| ES2440317T3 | Spain | T3 | |
| PL2322525T3 | Poland | T3 |
Numbers
- Application
- 7724372
Titles2
- German
- PURINDERIVATE ZUR VERWENDUNG ALS ADENOSIN-A2A- REZEPTORAGONISTEN
- English
- PURINE DERIVATIVES FOR USE AS ADENOSINE A2A RECEPTOR AGONISTS
Classification
- CPC, 34
- C07D473/16
- A61P1/04
- C07D473/34
- A61P1/12
- A61P1/16
- A61P3/10
- A61P7/00
- A61P7/06
- A61P9/10
- A61P9/12
- A61P11/00
- A61P11/02
- A61P11/06
- A61P11/08
- A61P11/14
- A61P13/12
- A61P17/00
- A61P17/02
- A61P17/04
- A61P17/06
- A61P17/14
- A61P19/00
- A61P19/02
- A61P21/00
- A61P21/04
- A61P25/00
- A61P25/20
- A61P27/02
- A61P27/06
- A61P29/00
- A61P37/06
- A61P37/08
- A61P43/00
- A61K31/52
- IPC, 7
- C07D473 16
- A61K31 52
- A61K31 7076
- A61P29 00
- C07D473 18
- C07D473 34
- C07H19 167